LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. director Lori Goltermann has filed an initial Form 3, which is a statement of beneficial ownership for new insiders. This filing establishes her status as a reporting person but does not report any share purchases, sales, or other transactions.
LifeStance Health Group, Inc. director Justice Thurman has filed an initial Form 3 ownership report. The filing does not list any buy, sell, or other insider transactions or derivative positions, indicating that this is a baseline disclosure of status as a reporting person rather than a trading event.
LifeStance Health Group, Inc. filed an initial ownership report (Form 3) for Shabab Safwan, who is listed as a director of the company. The filing does not report any stock or option transactions, so it serves only to establish Safwan as a reporting insider under SEC rules.
LifeStance Health Group, Inc. reported changes to its board of directors. Jeffrey Rhodes resigned from the board and all committees effective immediately, and the company stated his resignation was not due to any disagreement with the company.
To fill board vacancies, the board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as directors. Mr. Justice and Ms. Goltermann were named Class II directors, serving until the 2029 annual meeting of stockholders, while Mr. Shabab was named a Class III director, serving until the 2027 meeting.
Mr. Justice joined the audit committee and the quality and compliance committee, Ms. Goltermann joined the compensation and nominating and governance committees, and Mr. Shabab joined the nomination and governance committee. Under the 2021 Equity Incentive Plan, Mr. Justice and Ms. Goltermann each received 35,492 restricted stock units, which vest under a time- and performance-based agreement, subject to their continued board service.
LifeStance Health Group director-related entities sold a sizable block of shares. On June 26, 2026, entities associated with director Robert Bessler — Shama LLC and Vitthal LLC — executed open-market sales totaling 894,337 shares of LifeStance common stock at a weighted average price of $10.13 per share.
The filing states these sales occurred in multiple transactions within a price range of $10.00 to $10.295 per share. After these transactions, Shama LLC held 656,560 shares and Vitthal LLC held 539,763 shares of common stock. The report also shows Bessler with 57,619 shares held directly and 36,363 shares held indirectly in a separate position. Footnotes emphasize that he disclaims beneficial ownership of certain securities except to the extent of his pecuniary interest.
LifeStance Health Group reported sales of Common Stock via Form 144 by related holders. The excerpt lists four transactions: 5,101 shares for $35,749.48, 7,752 shares for $54,267.10, 62,147 shares for $438,074.20, and 75,000 shares for $641,580.00. The filing also shows 387,834,432 shares outstanding as of 06/26/2026.
LifeStance Health Group’s Chief Technology Officer, Vukasin Paunovich, reported a tax-related share withholding tied to vested restricted stock units. On June 11, 2026, 17,456 shares of common stock were withheld by the company at $8.61 per share to cover tax obligations, and this was not an open-market sale. After this net settlement, Paunovich directly holds 291,840 shares of LifeStance common stock.
LifeStance Health Group, Inc. held its annual stockholder meeting on June 2, 2026. Stockholders elected Class II directors David Bourdon and Robert Bessler to three-year terms, with 244,968,319 and 280,015,618 votes cast for their elections, respectively.
Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ended December 31, 2026, with 357,756,707 votes for the proposal. In addition, stockholders approved, on a non-binding advisory basis, the company’s named executive officer compensation, with 322,904,359 votes in favor.
LifeStance Health Group, Inc. amendment to a Schedule 13G/A reports that TPG VIII Lynnwood (via TPG GP A, LLC and affiliated Reporting Persons James G. Coulter and Jon Winkelried) is associated with 111,744,614 shares of Common Stock, representing 29.3% of the class. The percentage is calculated based on 381,834,432 shares outstanding as of May 12, 2026, as cited from a Prospectus Supplement filed on May 8, 2026. The filing states shared voting and shared dispositive power over the reported shares and includes a joint filing agreement and related disclaimers of beneficial ownership to the extent of pecuniary interest.
LifeStance Health Group director Robert Bessler reported indirect open-market sales of company stock by entities associated with him. On May 12, 2026, Shama LLC and Vitthal LLC each sold 287,517 shares of LifeStance common stock at $8.02 per share, for a total of 575,034 shares.
After these transactions, Shama LLC held 1,103,729 shares and Vitthal LLC held 986,931 shares. Separate holding entries show 57,619 shares held directly by Bessler and 36,363 shares held indirectly. Footnotes state that Bessler disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.